Remdesivir versus standard-of-care for severe Coronavirus disease 2019 Infection: an analysis of 28-day mortality
| العنوان: | Remdesivir versus standard-of-care for severe Coronavirus disease 2019 Infection: an analysis of 28-day mortality |
|---|---|
| المؤلفون: | Diana M. Brainard, Dax Kurbegov, Marta Boffito, Diego Ripamonti, Stéphane De Wit, Su Wang, Anand P Chokkalingam, Hao Hu, Antonella Castagna, Richard Haubrich, George Wu, George A. Diaz, Robert L. Gottlieb, Esteban Martínez, Anu Osinusi, Helena Diaz-Cuervo, David C. Lye, I-Heng Lee, Bindu Balani, Shin Woo Kim, Jose I Bernardino, Kathleen M. Mullane, Lanjia Lin, Katherine K. Perez, Raffaele Bruno, Susan Olender, Francesco Giuseppe De Rosa, Theresa L. Walunas, Parag Goyal |
| المساهمون: | Lee Kong Chian School of Medicine (LKCMedicine), Tan Tock Seng Hospital, Yong Loo Lin School of Medicine, Olender, S. A., Walunas, T. L., Martinez, E., Perez, K. K., Castagna, A., Wang, S., Kurbegov, D., Goyal, P., Ripamonti, D., Balani, B., De Rosa, F. G., De Wit, S., Kim, S. -W., Diaz, G., Bruno, R., Mullane, K. M., Lye, D. C., Gottlieb, R. L., Haubrich, R. H., Chokkalingam, A. P., Wu, G., Diaz-Cuervo, H., Brainard, D. M., Lee, I. -H., Hu, H., Lin, L., Osinusi, A. O., Bernardino, J. I., Boffito, M. |
| المصدر: | Open Forum Infectious Diseases Open Forum Infectious Diseases, 8 (7 |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Remdesivir, remdesivir, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Major Article, Medicine [Science], 030212 general & internal medicine, Mortality, Oxygen saturation (medicine), business.industry, SARS-CoV-2, Mortality rate, COVID-19, mortality, Généralités, Odds ratio, Confidence interval, Infectious Diseases, AcademicSubjects/MED00290, Oncology, Propensity score matching, Cohort, business |
| الوصف: | Background: Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials. Methods: This was the final day 28 comparative analysis of data from a phase 3, randomized, open-label study comparing 2 remdesivir regimens (5 vs 10 days, combined for this analysis [remdesivir cohort]) and a real-world retrospective longitudinal cohort study of patients receiving standard-of-care treatment (nonremdesivir cohort). Eligible patients, aged ≥18 years, had confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), oxygen saturation ≤94% on room air or required supplemental oxygen, with pulmonary infiltrates. Propensity score matching (up to 1:10 ratio) was used to ensure comparable populations. We assessed day 14 clinical recovery (determined using a 7-point ordinal scale) and day 28 all-cause mortality (coprimary endpoints). Results: A total of 368 (remdesivir) and 1399 (nonremdesivir) patients were included in the matched analysis. The day 14 clinical recovery rate was significantly higher among the remdesivir versus the nonremdesivir cohort (65.2% vs 57.1%; odds ratio [OR], 1.49; 95% confidence interval [CI], 1.16-1.90; P=0.002). The day 28 mortality rate was significantly lower in the remdesivir cohort versus the nonremdesivir cohort (12.0% vs 16.2%; OR, 0.67; 95% CI, 0.47-.95; P=.03). Conclusions: Remdesivir was associated with significantly higher rates of day 14 clinical recovery, and lower day 28 mortality, compared with standard-of-care treatment in hospitalized patients with COVID-19. These data, taken together, support the use of remdesivir to improve clinical recovery and decrease mortality from SARS-CoV-2 infection. SCOPUS: ar.j info:eu-repo/semantics/published |
| وصف الملف: | application/pdf; 1 full-text file(s): application/pdf |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85b9eb3ae5cdb4a16426d314331095b6Test https://hdl.handle.net/10356/154077Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....85b9eb3ae5cdb4a16426d314331095b6 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |